Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Breast Cancer
Interventions: Paclitaxel, 5-Fluorouracil, Epirubicin, Cyclophosphamide, RAD001; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: GameDay Ready, Walking and General Health Education; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 20 Years to 70 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Mercaptopurine, Methotrexate, Methylprednisolone, Prednisone, Rituximab, Tagraxofusp-erzs, Venetoclax, Vincristine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain
Interventions: Pain Catastrophizing Class, Health Education; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Deep Sedation, Anesthesia, General
Interventions: Sevoflurane group, Propofol group; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Postoperative Pain
Interventions: Maxigesic® IV; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Pasadena, Maryland • Chapel Hill, North Carolina

Conditions: Healthy Volunteers
Interventions: There is no intervention; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bone Cancer, Ewing's Sarcoma
Interventions: Irinotecan, Vincristine, Temozolomide, Doxorubicin, Cytoxan, Pegfilgrastim; Drug
Lead sponsor: Stanford University; Other
Eligibility: 13 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Alcohol Impairment, Nystagmus, Virtual Reality, Lack of Smooth Pursuit, Impairment, Alcohol Intoxication, Intoxication
Interventions: Alcoholic beverage; Drug
Lead sponsor: Gaize; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Gliosarcoma, Adult, Gliosarcoma of Brain
Interventions: C134; Drug
Lead sponsor: James Markert, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 634
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more

Conditions: Reversal of Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more

Conditions: Insomnia
Interventions: Mindfulness-Based Stress Reduction, Mindfulness-Based Therapy for Insomnia, Wait-List + Behavioral Therapy for Insomnia; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Posttraumatic Stress Disorder
Interventions: Prolonged Exposure for Primary Care (PE-PC), Treatment as Usual; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Decatur, Georgia • Charleston, South Carolina

Conditions: Posttraumatic Stress Disorder
Interventions: COGENT (Cognitive ENhancement Training), ST (Sham Training); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cardiac Toxicity, Sarcoma
Interventions: cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, conventional surgery; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 132
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 97 more

Conditions: Malaria
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2,101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Physical Inactivity, Poor Diet
Interventions: Brief Motivational Intervention, Educational information; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: COVID-19, Sleep, Immunization; Infection, Physical Inactivity, Blood Pressure, Diet Habit, Mental Health Wellness 1
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Major Depressive Disorder, Unipolar, Non-psychotic Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 62 Years
Enrollment: 40 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Barrett Esophagus
Interventions: Photoacoustic endoscopy, Endoscopic ultrasound (standard of care), Endoscopic surgery (standard of care); Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dental Implant, Immediate Dental Implant, Soft Tissue Augmentation
Interventions: Immediate implant, SCTG, ADM; Device · Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma (MM)
Interventions: Immediate intervention, Waitlist; Behavioral · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Maywood, Illinois • Milwaukee, Wisconsin

Conditions: Autism, Autism Spectrum Disorder, Nonverbal Learning Disability
Interventions: Memantine Hydrochloride, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Investigating the Effects of the "GameDay Ready" Behavioral Weight Management Program for Black Men Living in the Rural South

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Single Session Class to Reduce Opioid Use in Chronic Pain

Addition of Nitrous Oxide and Its Effects on Depth of Anesthesia

Maxigesic® IV Phase 3 Exposure Study

General Pre-Trial Screening Protocol for Infectious Diseases Research

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Alcohol Impairment Detection in Healthy Adult Users With the Gaize Device

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Mindfulness-Based Approaches to Insomnia

Improving Function Through Primary Care Treatment of Posttraumatic Stress Disorder (PTSD)

Cognitive Training for Functioning in PTSD

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Malaria Clinical Trials Center General Screening

Brief Motivational Intervention to Increase Physical Activity and Fruit/Vegetable Intake

COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise

Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics

Photoacoustic Endoscopy of Barrett's Esophagus

Esthetic Outcomes Following Immediate Implant Combine With Soft Tissue Augmentation

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions